Outer surface protein C peptide derived from borrelia burgdorferi sensu stricto as a target for serodiagnosis of early lyme disease

Clinical and Vaccine Immunology

Volumn 20, Issue 4, 2013, Pages 474-481

  Arnaboldi, Paul M ^a,b   Seedarnee, Rudra ^b   Sambir, Mariya ^a,b   Callister, Steven M ^c   Imparato, Josephine A ^a   Dattwylera, Raymond J ^b  

^a Biopeptides Corp   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OSPC PROTEIN; OSPC1 PROTEIN; PEPC10 PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ARTICLE; BORRELIA BURGDORFERI; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAGIN TEST; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORRELIA BURGDORFERI; EARLY DIAGNOSIS; EPITOPE MAPPING; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYME DISEASE; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 84876484354     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00608-12     Document Type: Article

References (38)

1. Stanek G, Wormser GP, Gray J, Strle F. 2012. Lyme borreliosis. Lancet 379:461-473.
2. Steere AC. 2001. Lyme disease. N. Engl. J. Med. 345:115-125.
3. Dattwyler RJ. 2010. A commentary on the treatment of early Lyme disease. Clin. Infect. Dis. 50:521-522.
4. Coyle PK, Schutzer SE. 2002. Neurologic aspects of Lyme disease. Med. Clin. North Am. 86:261-284.
5. Steere AC, Schoen RT, Taylor E. 1987. The clinical evolution of Lyme arthritis. Ann. Intern. Med. 107:725-731.
6. Nardelli DT, Callister SM, Schell RF. 2008. Lyme arthritis: Current concepts and a change in paradigm. Clin. Vaccine Immunol. 15:21-34.
7. Halperin JJ. 2009. Nervous system Lyme disease: Diagnosis and treatment. Rev. Neurol. Dis. 6:4-12.
8. Raveche ES, Schutzer SE, Fernandes H, Bateman H, McCarthy BA, Nickell SP, Cunningham MW. 2005. Evidence of Borrelia autoimmunity-induced component of Lyme carditis and arthritis. J. Clin. Microbiol. 43:850-856.
9. Centers for Disease Control and Prevention (CDC). 1995. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.MMWRMorb. Mortal. Wkly. Rep. 44:590-591.
10. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. 2005. Diagnosis of Lyme borreliosis. Clin. Microbiol. Rev. 18:484-509.
11. Porwancher R. 1999. A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease. J. Infect. Dis. 179:1021-1024.
12. Seriburi V, Ndukwe N, Chang Z, Cox ME, Wormser GP. 2012. High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin. Microbiol. Infect. 18:1236-1240.
13. Gomes-Solecki MJ, Wormser GP, Persing DH, Berger BW, Glass JD, Yang X, Dattwyler RJ. 2001. A first-tier rapid assay for the serodiagnosis of Borrelia burgdorferi infection. Arch. Intern. Med. 161:2015-2020.
14. Wang I, Dykhuizen DE, Qiu W, Dunn JJ, Bosler EM, Luft BJ. 1999. Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto. Genetics 151:15-30.
15. Porwancher R. 2003. Improving the specificity of recombinant immunoassays for Lyme disease. J. Clin. Microbiol. 41:2791.
16. Branda JA, Aguero-Rosenfeld ME, Ferraro MJ, Johnson BJB, Wormser GP, Steere AC. 2010. 2-Tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin. Infect. Dis. 50:20-26.
17. Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. 2011. Twotiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin. Infect. Dis. 53:541-547.
18. Barbour AG, Travinsky B. 2010. Evolution and distribution of the ospC gene, a transferable serotype determinant of Borrelia burgdorferi. mBio 1:e00153-10. doi:10.1128/mBio.00153-10.
19. Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD, Jr, Philipp MT, Steere AC, Wormser GP, Marques AR, Johnson BJ. 2003. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J. Infect. Dis. 187:1187-1199.
20. Johnson BJB, Robbins KE, Bailey RE, Cao B, Sviat SL, Craven RB, Mayer LW, Dennis DT. 1996. Serodiagnosis of Lyme disease: Accuracy of a two-step approach using a flagella-based ELISA and immunoblotting. J. Infect. Dis. 174:346-353.
21. Anonymous. 1997. Case definitions for infectious conditions under public health surveillance. MMWR Recommend. Rep. 46:1-55.
22. Nowakowski J, Schwartz I, Liveris D, Wang G, Aguero-Rosenfeld ME, Girao G, McKenna D, Nadelman RB, Cavaliere LF, Wormser GP, Lyme Disease Study Group. 2001. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: A comparison of different techniques. Clin. Infect. Dis. 33:2023-2027.
23. Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. 1999. Sensitive and specific serodiagnosis of Lyme disease by enzymelinked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J. Clin. Microbiol. 37:3990-3996.
24. Gomes-Solecki MJ, Meirelles L, Glass J, Dattwyler RJ. 2007. Epitope length, genospecies dependency, and serum panel effect in the IR6 enzyme-linked immunosorbent assay for detection of antibodies to Borrelia burgdorferi. Clin. Vaccine Immunol. 14:875-879.
25. Ohnishi J, Schneider B, Messer WB, Piesman J, de Silva AM. 2003. Genetic variation at the vlsE locus of Borrelia burgdorferi within ticks and mice over the course of a single transmission cycle. J. Bacteriol. 185:4432-4441.
26. Bykowski T, Woodman ME, Cooley AE, Brissette CA, Wallich R, Brade V, Kraiczy P, Stevenson B. 2008. Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): Expression patterns during the mammal-tick infection cycle. Int. J. Med. Microbiol. 298(Suppl 1):249-256.
27. Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, Nowakowski J, Marques A, Johnson BJB, Dumler JS. 2013. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn. Microbiol. Infect. Dis. 75:9-15.
28. Barbour AG, Jasinskas A, Kayala MA, Davies DH, Steere AC, Baldi P, Felgner PL. 2008. A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect. Immun. 76:3374-3389.
29. Tilly K, Krum JG, Bestor A, Jewett MW, Grimm D, Bueschel D, Byram R, Dorward D, VanRaden MJ, Stewart P, Rosa P. 2006. Borrelia burgdorferi OspC protein required exclusively in a crucial early stage of mammalian infection. Infect. Immun. 74:3554-3564.
30. Mathiesen MJ, Christiansen M, Hansen K, Holm A, Åsbrink E, Theisen M. 1998. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J. Clin. Microbiol. 36:3474-3479.
31. Panelius J, Lahdenne P, Heikkilla T, Peltomaa M, Oksi J, Seppala I. 2002. Recombinant OspC from Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii in the serodiagnosis of Lyme borreliosis. J. Med. Microbiol. 51:731-739.
32. Magnarelli LA, Fikrig E, Padula SJ, Anderson JF, Flavell RA. 1996. Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of Lyme borreliosis. J. Clin. Microbiol. 34:237-240.
33. Gerber MA, Shapiro ED, Bell GL, Sampieri A, Padula SJ. 1995. Recombinant outer surface protein C ELISA for the diagnosis of early Lyme disease. J. Infect. Dis. 171:724-727.
34. Kaiser R, Rauer S. 1999. Advantage of recombinant borrelial proteins for serodiagnosis of neuroborreliosis. J. Med. Microbiol. 48:5-10.
35. Earnhart CG, Marconi RT. 2007. OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine. Clin. Vaccine Immunol. 14:628-634.
36. Jauris-Heipke S, Liegl G, Preac-Mursic V, Rössler D, Schwab E, Soutschek E, Will G, Wilske B. 1995. Molecular analysis of genes encoding outer surface protein C (OspC) of Borrelia burgdorferi sensu lato: Relationship to ospA genotype and evidence of lateral gene exchange of ospC. J. Clin. Microbiol. 33:1860-1866.
37. Earnhart CG, Buckles EL, Dumler JS, Marconi RT. 2005. Demonstration of OspC type diversity in invasive human Lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response. Infect. Immun. 73:7869-7877.
38. Magnarelli LA, Ijdo JW, Padula SJ, Flavell RA, Fikrig E. 2000. Serologic diagnosis of Lyme borreliosis by using enzyme-linked immunosorbent assays with recombinant antigens. J. Clin. Microbiol. 38: 1735-1739.